Review article: dose optimisation of infliximab for acute severe ulcerative colitis
Alimentary Pharmacology & Therapeutics2017Vol. 45(5), pp. 617–630
Citations Over TimeTop 10% of 2017 papers
P. Hindryckx, Gregor Novak, Niels Vande Casteele, Debby Laukens, Claire E. Parker, Lisa M. Shackelton, Neeraj Narula, Reena Khanna, Parambir S. Dulai, Barrett G. Levesque, William J. Sandborn, Geert D’Haens, Brian G. Feagan, Vipul Jairath
Abstract
Uncontrolled studies suggest a benefit for infliximab dose optimisation in patients with acute severe UC. A randomised controlled trial in acute severe UC patients comparing a personalised infliximab dose-optimisation strategy with conventional dosing is a research priority.
Related Papers
- → Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006(2007)116 cited
- → Utilization and surgical procedures following Colectomy in patients with Ulcerative Colitis(2009)
- → 21 NATURAL HISTORY OF COLECTOMY AMONG HOSPITALIZED PATIENTS WITH ULCERATIVE COLITIS IN THE CONTEMPORARY ERA OF BIOLOGICS(2020)
- → Predictors of the efficacy of infliximab in patients with ulcerative colitis(2022)